Investment Pitches

Pitch Summary:
DoorDash is the leading food-delivery platform in the United States by market share. Shares declined after the company announced plans to invest several hundred million additional dollars in new initiatives and platform development in 2026. We believe the market reaction created an attractive valuation opportunity. We believe DoorDash has earned the right to invest from a position of strength, supported by disciplined monitoring of returns on investment. The company has a broad set of compelling opportunities, including its global technology platform supporting DoorDash, Wolt, and Deliveroo, the expansion of DashMart fulfillment, and new products for restaurants and merchants. These investments are underpinned by strong operating momentum. In the most recent quarter, DoorDash grew gross order volume 25 percent year over year, its fastest pace in two years. Revenue increased 27 percent and adjusted EBITDA rose 41 percent, both exceeding expectations. Take rate continues to improve, driven by advertising growth, lower credits and refunds, and delivery efficiencies.

BSD Analysis:
DoorDash is no longer a pandemic trade — it’s local logistics infrastructure at scale. The core advantage is density: more merchants, more drivers, more orders, which lowers unit costs competitors can’t match. Food delivery is just the entry point; groceries, retail, and convenience are where the long-term value compounds. Margins have improved meaningfully as management shifted from growth-at-any-cost to operational discipline. Regulation and labor costs remain a headline risk, but scale softens the impact. Merchant services and advertising are underappreciated profit levers. International losses are the tax investors pay for optionality. This is not a simple delivery app. It’s a last-mile network embedding itself into daily commerce.

Pitch Summary:
Axon Enterprise is a leading provider of public-safety technology, including body cameras, software, and the TASER electroshock device. Shares declined following third-quarter 2025 results, weighed down by a GAAP net loss and a 50-basis-point drop in adjusted gross margins due to tariffs and product mix. Investor skepticism toward Axon’s $1.4 billion push into emergency dispatch, through the Prepared and Carbyne acquisitions, also pressured the stock. The market remains cautious about Axon’s return to a category where previous industry efforts have struggled. We believe this overlooks the strategic shift toward a cloud-native, AI-enabled platform integrated into Axon’s broader public-safety ecosystem. Despite the selloff, Axon delivered its seventh consecutive quarter of revenue growth above 30 percent, raised full-year guidance, and maintained 124 percent net revenue retention. Annual recurring revenue rose 41 percent year over year. In our view, the stock’s decline, which was amplified by a broader pullback in high-growth stocks during November, presents a compelling valuation opportunity for this public-safety technology leader.

BSD Analysis:
Axon owns a vertically integrated ecosystem spanning tasers, body cameras, and evidence management software that agencies don’t rip out lightly. Switching costs are brutal once training, workflows, and data retention are standardized. Recurring software revenue is now the economic engine, not hardware sales. Public safety budgets favor incumbents with compliance and reliability, especially as accountability demands rise. Investors debate valuation while contract visibility keeps lengthening. AI-enabled evidence tools deepen lock-in rather than commoditizing it. International expansion adds runway without reinventing the model. This is govtech infrastructure where controversy doesn’t erase demand.

Pitch Summary:
Netflix is the world’s largest producer and distributor of streaming video content by subscriber count. Its stock has come under pressure amid investor skepticism over its proposed acquisition of Warner Bros Discovery’s studio and streaming assets. The deal would be Netflix’s largest to date and is expected to be funded through a mix of cash and debt. A competing bid from Paramount has added to the uncertainty. We believe the acquisition would strengthen Netflix’s business and is likely to withstand antitrust review. We have long viewed studio ownership as a strategic fit for Netflix. Combining valuable intellectual property with the company’s global distribution platform could boost overall viewership and improve pricing power. Our research suggests that the combination of leading IP and distribution leads to higher engagement. While antitrust remains a risk, we believe Netflix has a credible case based on the evolving definition of the video market, as streaming and linear content continue to converge.

BSD Analysis:
Netflix has crossed from growth experiment to global entertainment infrastructure with real operating leverage. Scale lets it amortize content costs better than any competitor, which is the entire game. The ad tier adds a second monetization engine without undermining subscriptions. Password-sharing enforcement proved demand elasticity was underestimated. International markets drive most incremental growth quietly. Investors fixate on content spend and miss free cash flow inflection. Competition fragments libraries but consolidates distribution. This is media dominance finally behaving like a business.

Pitch Summary:
Taiwan Semiconductor (TSMC) is the world’s largest producer of leading-edge logic chips by market share. The company reported strong results for the most recent quarter. It continues to execute well on advanced-node yield improvements and capacity expansions to meet accelerating AI compute demand. TSMC remains a key beneficiary of this trend. New AI-related partnerships announced over the past several months support a growing multi-year revenue pipeline. Taiwanese media also reported potential price increases for 5nm and more advanced nodes next year, which could provide a meaningful revenue tailwind in 2026. TSMC is also ramping its overseas capacity, fast-tracking its Arizona facility to produce N2, and possibly A16, nodes to serve growing AI demand. We view the company as one of the strongest fits with our investment criteria, supported by its leadership in advanced manufacturing, deep customer relationships, and growing role in enabling next-generation technologies. TSMC remains a large holding across Sands Capital portfolios.

BSD Analysis:
TSMC is the single most critical manufacturer in the global tech stack, and nothing close exists as a substitute. Every serious AI, HPC, and advanced mobile roadmap is built around its process nodes. Capex is massive, but it hardens the moat rather than eroding returns. Customers optimize designs for TSMC’s yields, not competitors’ promises. Geopolitics dominate headlines yet also guarantee strategic support from governments and customers alike. Margins cycle, dominance does not. Dependency keeps deepening while valuation debates repeat. This is monopoly-like manufacturing with political noise layered on top.

Pitch Summary:
Titan is India’s largest specialty jewelry retailer by store count and market share. The company reported a strong quarter, with revenue up 29 percent and operating income rising 52 percent year over year. While higher gold prices limited volume growth, pricing strength drove jewelry segment sales up 29 percent. Operating margins expanded 140 basis points, supported by cost management and operating leverage. The company continues to execute well, offering products across distinct socioeconomic segments while expanding its retail footprint. The festive season surge highlights strong customer affinity for Titan’s brands. The company is also increasing investment in lab-grown diamonds to align with evolving consumer preferences, citing attractive unit economics. We continue to view Titan as a core emerging market holding.

BSD Analysis:
Titan is a rare emerging-market luxury and discretionary compounder built on trust, not trendiness. Its jewelry business monetizes India’s shift from informal gold buying to branded retail with compliance and transparency. Pricing power comes from design, purity assurance, and financing access rather than raw gold prices. Watches and eyewear add diversification without diluting brand equity. Investors worry about gold volatility and consumer cycles, but weddings and savings behavior are structurally resilient. Store expansion and digital integration deepen reach without reckless capital spend. This is formalization alpha playing out over decades. Culture is the moat.

Pitch Summary:
Galderma is a Swiss dermatology company. Its most recent results beat expectations across product categories, and the company raised full-year revenue and EBITDA margin guidance. Nemluvio, Galderma’s treatment for chronic skin conditions, now accounts for 7 percent of new prescriptions in atopic dermatitis—a $20 billion market. Even if Nemluvio stopped growing, it would already be tracking ahead of consensus peak sales estimates. We are also encouraged by market share gains in the European Union for Relfydess, a next-generation botulinum toxin. Our research shows that dermatologists are increasingly choosing Relfydess over Botox. We believe the market underestimates both its share gain potential and its revenue contribution. Galderma expects to launch Relfydess in the United States in 2026.

BSD Analysis:
Galderma sits at the crossroads of medical dermatology and aesthetics, where patients pay out of pocket and outcomes matter. Demand is driven by long-term trends in skin health, aging, and self-care, not reimbursement cycles. Brands like Restylane and Cetaphil anchor both physician and consumer relationships. Aesthetics can be cyclical at the margin, but core dermatology is resilient. R&D spend reinforces brand credibility rather than chasing moonshots. Global scale supports margin expansion as mix shifts toward higher-value injectables. Competition exists, but switching costs are real at the physician level. This is not beauty retail. It’s medical-grade aesthetics with a long runway.

Pitch Summary:
Intuitive Surgical is a leading provider of robotic surgical systems. The business reported strong third-quarter 2025 results, exceeding expectations across key metrics. Procedure growth, which we view as the best leading indicator for future robot system demand, was a standout. Robust volumes point to growing demand for robotic systems as hospitals expand surgical capacity. Expectations had been low heading into the quarter, with concerns around hospital capital expenditures and instrument reprocessing weighing on the stock. Against that backdrop, Intuitive’s $2 billion share repurchase signaled confidence—and the results validated it. The company placed 33 percent more da Vinci 5 systems quarter over quarter, marking early momentum in what we see as its most significant product cycle to date. It also began offering refurbished Xi systems in cost-sensitive markets, with strong initial uptake. Looking ahead, we expect procedure growth to drive higher system and instrument pricing and servicing revenue. Software and AI monetization represent additional upside not yet reflected in consensus expectations.

BSD Analysis:
Intuitive Surgical owns robotic surgery because it solved workflow, training, and trust — not just hardware. Hospitals don’t switch platforms lightly once surgeons are trained and procedures standardized. Procedure volumes, not capital sales, drive long-term growth and margin expansion. The installed base creates a recurring stream of high-margin instruments and service revenue. Competition is coming, but inertia is a powerful force in operating rooms. Innovation here is evolutionary, not disruptive, and that favors the incumbent. Valuation always looks expensive until you understand the durability. This is not medtech hype. It’s procedural infrastructure with compounding economics.

Pitch Summary:
Alphabet’s recent results and product launches have reshaped its AI narrative. Once viewed as lagging in the space, it is now seen as a credible leader and rival to OpenAI. Third-quarter 2025 results were strong. Search and paid clicks both accelerated, with paid clicks growing at their fastest pace in two years. Management cited AI Overviews and the new AI Mode as key drivers of user engagement. Google Cloud reached a $60 billion run rate and is growing at a pace similar to AWS at the same scale. The subscriptions, platforms, and devices segment now generates $50 billion annually and grew more than 20 percent year over year. YouTube ad revenue rose 14 percent, solid for a $40 billion business. Alphabet also launched Gemini 3, its latest AI model, which led industry benchmarks in text and image tasks. Meta Platforms plans to adopt Alphabet’s custom AI chips, TPUs, in its data centers beginning in 2027.

BSD Analysis:
Alphabet remains one of the most mispriced mega-cap franchises in the market given its dominance and cash flow durability. Search is still the default behavior for billions of users, despite years of disruption fears. AI doesn’t kill Google — it deepens engagement and monetization if executed correctly. YouTube continues to mature into a cash-generating media platform with multiple revenue levers. Google Cloud has crossed the profitability threshold, adding a new earnings pillar. Regulatory pressure is constant, but user behavior hasn’t meaningfully changed. The balance sheet is absurdly strong, enabling buybacks alongside heavy AI investment. This is not a declining platform story. It’s a dominant tollbooth adapting in real time.

Pitch Summary:
EssilorLuxottica is the world’s largest vertically integrated eyewear company. Its scale enables pricing power, innovation, and efficiency across the value chain. Smart glasses represent a significant upside driver, supported by a partnership with Meta and growing demand for AI-enabled wearables. With strong recurring revenue, premium brands, and exposure to long-term health and technology trends, we believe EssilorLuxottica is well positioned to deliver sustainable value over time.

BSD Analysis:
EssilorLuxottica is vertical integration taken to its logical extreme, controlling lenses, frames, brands, and distribution in a category people can’t opt out of. Vision correction demand is demographic destiny, not discretionary spending. The Ray-Ban and Oakley brands monetize fashion while Essilor monetizes medical necessity, a rare dual-engine model. Smart glasses and wearable tech are optional upside, not required for the thesis. Pricing power exists because eyesight doesn’t wait for promotions. Investors underappreciate how hard it is to replicate this ecosystem end-to-end. Scale improves margins quietly through manufacturing and distribution leverage. This is healthcare infrastructure wearing a luxury multiple for good reason.

Pitch Summary:
MercadoLibre is the largest ecommerce and fintech ecosystem in Latin America by market share. Shares came under pressure due to rising competition in Brazil. Our research suggests investments are strengthening long-term unit economics, with volume growth, logistics density, and loyalty initiatives reinforcing its moat. The stock now trades at its lowest forward earnings multiple in nearly a decade.

BSD Analysis:
MercadoLibre is the most complete digital ecosystem in Latin America, combining commerce, logistics, payments, and credit in markets where infrastructure is weak. That weakness is the moat — MercadoLibre built what governments and banks didn’t. Mercado Pago is evolving into a full-stack fintech with real profitability, not just volume. Logistics scale continues to separate winners from wishful competitors. Currency volatility and politics are constant, but the company compounds through chaos. Margins are expanding without sacrificing growth, which is rare. Execution has been consistently excellent for years. This is not an emerging-market gamble anymore. It’s a dominant platform still early in its earnings curve.

Pitch Summary:
Ferrari shares declined after the company lowered its 2030 EV sales target. We believe this reflects strategic discipline rather than weakness. Ferrari continues to deliver strong financial results while investing in electrification with flexibility across powertrains. Revenue, EBIT, and EPS grew strongly despite minimal shipment growth, underscoring pricing power and brand strength.

BSD Analysis:
Ferrari is the cleanest luxury business in the world because it refuses to grow. Scarcity is the strategy, not a byproduct. Demand vastly exceeds supply, giving Ferrari pricing power that most brands only pretend to have. Customers wait years — and happily pay more — which tells you everything about brand equity. Margins are elite because Ferrari sells emotion, not transportation. Electrification is a risk for mass automakers, but a design opportunity for Ferrari. Capital intensity is low relative to pricing power. This is not an auto stock. It’s a luxury asset with manufacturing attached.

Pitch Summary:
Spotify is the world’s largest subscription streaming audio platform by market share. Its valuation came under pressure as AI-generated music raised concerns about disintermediation. We view this risk as overstated, as Spotify is already integrating AI across its platform. We expect accelerating revenue growth and steady margin improvement, supported by updated agreements with major record labels that should enhance pricing power, particularly in developed markets.

BSD Analysis:
Spotify owns the global audio relationship, even if the economics still frustrate investors. Scale matters here — negotiating leverage with labels improves as Spotify grows, not shrinks. The real upside lies in margin expansion through podcasts, audiobooks, and ad monetization, not subscription pricing alone. Cost discipline has improved, proving this business doesn’t need to burn cash forever. Competition from Big Tech exists, but Spotify’s product focus and discovery algorithms still win on engagement. Free users are not a flaw — they’re a funnel. The platform’s data advantage compounds quietly. This is not a broken model. It’s a long game where operating leverage arrives late but hard.

Pitch Summary:
Ajinomoto is the world’s largest producer of amino acids by market share. Shares declined after results as investors focused on persistent challenges in the Frozen Foods segment and near-term earnings risk. While Functional Materials and Healthcare delivered solid growth and operating cash flow improved, significantly lower sales and profit in Frozen Foods raised concerns. Despite weakened sentiment, long-term fundamentals in Ajinomoto’s higher-growth businesses remain intact, and management reaffirmed full-year guidance.

BSD Analysis:
Ajinomoto looks like a traditional food company until you realize it quietly sits at the center of global protein, seasoning, and biotech supply chains. MSG is the headline, but the real value is amino acid manufacturing expertise that’s incredibly hard to replicate. That know-how extends into pharmaceuticals, animal nutrition, and specialty ingredients with much better economics than packaged food. Pricing power exists because customers buy functionality, not branding. Capital allocation has improved meaningfully, with more focus on ROIC and less on empire-building. Demand is defensive, but growth comes from applications, not calories. This is not a Japan consumer laggard. It’s industrial biochemistry hiding inside a food label. Ajinomoto compounds by being essential, not exciting.

Pitch Summary:
Sea is a Southeast Asian internet platform with businesses in gaming, ecommerce, and fintech. After seven consecutive quarters of exceeding consensus expectations, management shifted its focus to investing in logistics and user engagement, which is expected to weigh on margins in the near term. We believe the market is overreacting to spending that should ultimately strengthen Sea’s competitive position and long-term earnings power. We still expect Shopee to grow EBITDA by more than 30 percent in 2026 and believe Sea’s overall revenue and EBITDA can double and triple, respectively, by 2030.

BSD Analysis:
Sea is a volatile platform story spanning e-commerce, digital payments, and gaming in emerging markets. Shopee’s scale advantage matters more as competitors pull back spending. Profitability improvements showed the model can flex when discipline replaces growth-at-any-cost. Investors remain scarred by past cash burn and macro swings. Yet digital penetration across Southeast Asia continues to rise. Gaming cash flow still funds optionality elsewhere. This is platform leverage with scars, not a broken business. Execution, not ambition, decides the outcome.

Pitch Summary:
Shopify is the leading global ecommerce platform enabling the next generation of retail. In the third quarter, gross merchandise value rose 28 percent year over year—its strongest growth in four years and twelfth consecutive quarter of stable or accelerating performance. Growth was broad-based across geographies, verticals, and merchant sizes, highlighted by a meaningful acceleration in GMV per merchant and merchant services growth, driven by payments adoption. New client wins with brands such as Welch’s and FanDuel underscore momentum up-market. Strong share price performance also likely reflects Shopify increasingly being viewed as an AI beneficiary, set to benefit from its launch of AI-enabled merchant services and product discovery, supported by partnerships with OpenAI and improving advertising performance at Meta Platforms.

BSD Analysis:
Shopify is the operating system for independent commerce, monetizing entrepreneurs rather than competing with them. GMV growth fluctuates with consumer demand, but merchant dependency keeps rising. Payments, fulfillment tools, and services deepen monetization without forcing merchants into a walled garden. Investors fixate on growth deceleration and miss improving revenue quality. Scale drives margin expansion as platform costs amortize. AI features enhance merchant productivity rather than chasing novelty. Shopify doesn’t need to beat Amazon — it just needs to empower everyone else. This is commerce infrastructure, not a retail story.

Pitch Summary:
VAT Group (VAT) is the dominant provider of vacuum valves for semiconductor and industrial manufacturing processes. The company’s third-quarter update showed solid execution and results that aligned with expectations. Sales grew year over year, driven by backlog fulfillment, even as order intake remained muted amid cyclical softness in semiconductor equipment demand. Management guided to a softer fourth quarter and noted that margins would likely trend toward the low end of the target range due to volume and foreign exchange headwinds. Even so, the business is well positioned to benefit from rising AI-driven investment across the semiconductor value chain, which has the potential to accelerate demand for its vacuum valve technologies. Management expressed confidence in the long-term outlook and highlighted early signs of a recovery in semiconductor capital spending beginning in 2026.

BSD Analysis:
VAT Group owns a choke point in semiconductor manufacturing through its ultra-high-vacuum valves, components fabs cannot operate without. These parts are small-ticket but mission-critical, creating brutal switching costs and pricing power. Demand is cyclical, but technology roadmaps don’t disappear when capex pauses. As chip complexity increases, vacuum precision becomes more valuable, not less. Investors trade VAT like a generic semi supplier and miss the bottleneck economics. Margins reflect IP depth and qualification barriers, not volume chasing. When fab spending resumes, VAT’s operating leverage is extreme. This is picks-and-shovels dominance hiding in plain sight.

Pitch Summary:
Taiwan Semiconductor (TSMC) is the world’s largest producer of leading-edge logic chips by market share. The company reported strong results for the most recent quarter. It continues to execute well on advanced-node yield improvements and capacity expansions to meet accelerating AI compute demand. TSMC remains a key beneficiary of this trend. New AI-related partnerships announced over the past several months support a growing multi-year revenue pipeline. Taiwanese media also reported potential price increases for 5nm and more advanced nodes next year, which could provide a meaningful revenue tailwind in 2026.

BSD Analysis:
TSMC is the indispensable manufacturer at the center of the global technology stack, with every serious AI, HPC, and advanced mobile roadmap running through its fabs. Customers design chips around TSMC’s process nodes because no competitor matches its yield, scale, or execution reliability. Capex intensity is enormous, but it reinforces the moat rather than weakening it. Geopolitical risk dominates headlines, yet it also guarantees strategic support from governments and customers alike. Margins move with cycles, but technological leadership does not. Investors debate valuation while dependency quietly deepens. This is monopoly-like manufacturing with political noise layered on top. The digital economy quite literally runs through TSMC.

Pitch Summary:
Galderma is a Swiss dermatology company. Its most recent results beat expectations across product categories, and the company raised full-year revenue and EBITDA margin guidance. Nemluvio, Galderma’s treatment for chronic skin conditions, now accounts for 7 percent of new prescriptions in atopic dermatitis—a $20 billion market. Even if Nemluvio stopped growing, it would already be tracking ahead of consensus peak sales estimates. We are also encouraged by market share gains in the European Union for Relfydess, a next-generation botulinum toxin. Our research shows that dermatologists are increasingly choosing Relfydess over Botox. We believe the market underestimates both its share gain potential and its revenue contribution. Galderma expects to launch Relfydess in the United States in 2026.

BSD Analysis:
Galderma sits at the intersection of dermatology, aesthetics, and medical-grade skincare — a rare blend of science and consumer behavior. Demand is driven by self-pay procedures, which insulates the business from reimbursement politics. Brands like Restylane and Cetaphil create recurring engagement across medical and consumer channels. Growth is supported by global aesthetics adoption, not one-off product cycles. R&D spend actually matters here, reinforcing brand and physician trust. Margins expand as scale improves and mix shifts toward higher-value injectables. Cyclicality exists at the luxury edge, but core dermatology is resilient. This is not beauty hype. It’s medical aesthetics with a long runway.

Pitch Summary:
Broadcom (AVGO) is a leading semiconductor and infrastructure software company with strong positions in data center networking and custom ASIC solutions. We own the shares for the company’s favorable exposure to data center investment and differentiated silicon capabilities but remain underweight given stock volatility and our desire to limit portfolio semiconductor concentration risk at current valuations.

BSD Analysis:
Broadcom is the most ruthlessly efficient capital allocator in semiconductors. Its strategy is simple: sell mission-critical chips with no substitutes and extract maximum margin. Networking, custom silicon, and infrastructure software all benefit from AI-driven complexity. Customers complain about pricing — and then pay anyway. The VMware acquisition reinforces Broadcom’s grip on enterprise infrastructure, even if integration risk exists. Cash flow is enormous and aggressively returned to shareholders. Cyclicality exists, but the floor keeps rising. This is not innovation theater. It’s monopoly economics with discipline. Broadcom compounds by knowing exactly where it has leverage.

Pitch Summary:
Stryker (SYK) is a leading global medical technology company with strong franchises across orthopedics, surgical equipment, and neurotechnology. The company has consistently gained market share due to its first-to-market robotic surgery platform and strong execution in ambulatory surgery centers. Furthermore, growth expectations are boosted by secular tailwinds from an aging population and a long runway for international growth.

BSD Analysis:
Stryker is a medtech machine built around surgeon trust, procedural growth, and relentless execution. Orthopedics, robotics, and surgical tools create a portfolio where innovation actually translates into utilization. Once a hospital standardizes on Stryker, switching is operationally painful and clinically risky. Aging demographics and procedure backlogs provide structural tailwinds. Margins expand as instruments pull through consumables and implants. Acquisitions are frequent but usually disciplined and synergistic. Regulatory and reimbursement risks exist, but Stryker navigates them better than most peers. This is not speculative medtech. It’s procedure-driven compounding. Quietly dominant and very hard to displace.